{"pmid":32376901,"pmcid":"PMC7201395","title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.","text":["Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.","The COVID-19 pandemic caused by infection with SARS-CoV-2 has led to more than 200,000 deaths worldwide. Several studies have now established that the hyperinflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. Macrophages are a population of innate immune cells that sense and respond to microbial threats by producing inflammatory molecules that eliminate pathogens and promote tissue repair. However, a dysregulated macrophage response can be damaging to the host, as is seen in the macrophage activation syndrome induced by severe infections, including in infections with the related virus SARS-CoV. Here we describe the potentially pathological roles of macrophages during SARS-CoV-2 infection and discuss ongoing and prospective therapeutic strategies to modulate macrophage activation in patients with COVID-19.","Nat Rev Immunol","Merad, Miriam","Martin, Jerome C","32376901"],"abstract":["The COVID-19 pandemic caused by infection with SARS-CoV-2 has led to more than 200,000 deaths worldwide. Several studies have now established that the hyperinflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. Macrophages are a population of innate immune cells that sense and respond to microbial threats by producing inflammatory molecules that eliminate pathogens and promote tissue repair. However, a dysregulated macrophage response can be damaging to the host, as is seen in the macrophage activation syndrome induced by severe infections, including in infections with the related virus SARS-CoV. Here we describe the potentially pathological roles of macrophages during SARS-CoV-2 infection and discuss ongoing and prospective therapeutic strategies to modulate macrophage activation in patients with COVID-19."],"journal":"Nat Rev Immunol","authors":["Merad, Miriam","Martin, Jerome C"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376901","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41577-020-0331-4","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097376317440,"score":9.490897,"similar":[{"pmid":32470851,"pmcid":"PMC7214326","title":"Role of oxidized LDL-induced \"trained macrophages\" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.","text":["Role of oxidized LDL-induced \"trained macrophages\" in the pathogenesis of COVID-19 and benefits of pioglitazone: A hypothesis.","BACKGROUND AND AIMS: Older adults and people who have cardiovascular disorders (their common pathogenetic mechanism is progressive atherosclerosis) are at higher risk for severe illness from COVID-19 (coronavirus disease 2019). Their common pathogenetic mechanism is progressive atherosclerosis in which oxLDL (oxidized LDL) plays major role. Receptor-mediated uptake of oxLDL by the monocyte-derived macrophages activates the long-term epigenetic reprogramming of innate immunity, which is termed \"trained immunity.\" The aim of this work is to investigate the mechanisms and treatment possibilities that can control the activities of these specific macrophages. METHODS: Search in Medline and PubMed relevant articles on the trained immunity and cytokine storm of COVID-19. RESULTS AND CONCLUSIONS: When oxLDL-trained macrophages encounter SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in the lung, it causes unregulated cytokine secretion, leading to the alveolar damage. Therefore, blocking macrophage training by pioglitazone, a thiazolidinedione, could control the hyperactivation that the virus would trigger.","Diabetes Metab Syndr","Erol, Adnan","32470851"],"abstract":["BACKGROUND AND AIMS: Older adults and people who have cardiovascular disorders (their common pathogenetic mechanism is progressive atherosclerosis) are at higher risk for severe illness from COVID-19 (coronavirus disease 2019). Their common pathogenetic mechanism is progressive atherosclerosis in which oxLDL (oxidized LDL) plays major role. Receptor-mediated uptake of oxLDL by the monocyte-derived macrophages activates the long-term epigenetic reprogramming of innate immunity, which is termed \"trained immunity.\" The aim of this work is to investigate the mechanisms and treatment possibilities that can control the activities of these specific macrophages. METHODS: Search in Medline and PubMed relevant articles on the trained immunity and cytokine storm of COVID-19. RESULTS AND CONCLUSIONS: When oxLDL-trained macrophages encounter SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in the lung, it causes unregulated cytokine secretion, leading to the alveolar damage. Therefore, blocking macrophage training by pioglitazone, a thiazolidinedione, could control the hyperactivation that the virus would trigger."],"journal":"Diabetes Metab Syndr","authors":["Erol, Adnan"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470851","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.dsx.2020.05.007","keywords":["covid-19","macrophage","pioglitazone","oxldl"],"locations":["Medline"],"e_drugs":["2,4-thiazolidinedione","Pioglitazone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887181787136,"score":242.62828},{"pmid":32188729,"title":"Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages.","text":["Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages.","Coronaviruses encode multiple interferon antagonists that modulate the host response to virus replication. Here, we evaluated the host transcriptional response to infection with murine coronaviruses encoding independent mutations in one of two different viral antagonists: the deubiquitinase (DUB) within nonstructural protein 3 or the endoribonuclease (EndoU) within nonstructural protein 15. We used transcriptomics approaches to compare the scope and kinetics of the host response to the wild-type, DUBmut, and EndoUmut viruses in infected macrophages. We found that the EndoUmut virus activates a focused response predominantly involving type I interferons and interferon-related genes, whereas the WT and DUBmut viruses more broadly stimulate upregulation of over 2,800 genes, including networks associated with activating the unfolded protein response (UPR), and the proinflammatory response associated with viral pathogenesis. This study highlights the role of viral interferon antagonists in shaping the kinetics and magnitude of the host response during virus infection and demonstrates that inactivating a dominant viral antagonist, the coronavirus endoribonuclease, dramatically alters the host response in macrophages.ImportanceMacrophages are an important cell type during coronavirus infections because they \"notice\" the infection and respond by inducing type I interferons, which limits virus replication. In turn, coronaviruses encode proteins that mitigate the cell's ability to signal an interferon response. Here, we evaluated the host macrophage response to two independent mutant coronaviruses: one with reduced deubiquitinating activity (DUBmut) and the other containing an inactivated endoribonuclease (EndoUmut). We observed a rapid, robust, and focused response to the EndoUmut virus, which was characterized by enhanced expression of interferon and interferon-related genes. In contrast, wild-type virus and the DUBmut virus elicited a more limited interferon response and ultimately activated over 2,800 genes, including players in the unfolded protein response and pro-inflammatory pathways associated with progression of significant disease. This study reveals that EndoU activity substantially contributes to the ability of coronaviruses to evade the host innate response and to replicate in macrophages.","J Virol","Volk, Aaron","Hackbart, Matthew","Deng, Xufang","Cruz-Pulido, Yazmin","O'Brien, Amornrat","Baker, Susan C","32188729"],"abstract":["Coronaviruses encode multiple interferon antagonists that modulate the host response to virus replication. Here, we evaluated the host transcriptional response to infection with murine coronaviruses encoding independent mutations in one of two different viral antagonists: the deubiquitinase (DUB) within nonstructural protein 3 or the endoribonuclease (EndoU) within nonstructural protein 15. We used transcriptomics approaches to compare the scope and kinetics of the host response to the wild-type, DUBmut, and EndoUmut viruses in infected macrophages. We found that the EndoUmut virus activates a focused response predominantly involving type I interferons and interferon-related genes, whereas the WT and DUBmut viruses more broadly stimulate upregulation of over 2,800 genes, including networks associated with activating the unfolded protein response (UPR), and the proinflammatory response associated with viral pathogenesis. This study highlights the role of viral interferon antagonists in shaping the kinetics and magnitude of the host response during virus infection and demonstrates that inactivating a dominant viral antagonist, the coronavirus endoribonuclease, dramatically alters the host response in macrophages.ImportanceMacrophages are an important cell type during coronavirus infections because they \"notice\" the infection and respond by inducing type I interferons, which limits virus replication. In turn, coronaviruses encode proteins that mitigate the cell's ability to signal an interferon response. Here, we evaluated the host macrophage response to two independent mutant coronaviruses: one with reduced deubiquitinating activity (DUBmut) and the other containing an inactivated endoribonuclease (EndoUmut). We observed a rapid, robust, and focused response to the EndoUmut virus, which was characterized by enhanced expression of interferon and interferon-related genes. In contrast, wild-type virus and the DUBmut virus elicited a more limited interferon response and ultimately activated over 2,800 genes, including players in the unfolded protein response and pro-inflammatory pathways associated with progression of significant disease. This study reveals that EndoU activity substantially contributes to the ability of coronaviruses to evade the host innate response and to replicate in macrophages."],"journal":"J Virol","authors":["Volk, Aaron","Hackbart, Matthew","Deng, Xufang","Cruz-Pulido, Yazmin","O'Brien, Amornrat","Baker, Susan C"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32188729","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1128/JVI.00178-20","topics":["Mechanism"],"weight":1,"_version_":1666138490572636160,"score":234.98367},{"pmid":32464584,"title":"The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.","text":["The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.","BACKGROUND: SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute respiratory distress syndrome (ARDS), which can cause significant mortality, leading to concern that immunosuppressive treatments for multiple sclerosis and other disorders have significant risks for both infection and ARDS. OBJECTIVE: To examine the biology that potentially underpins immunity to the SARS-Cov-2 virus and the immunity-induced pathology related to COVID-19 and determine how this impinges on the use of current disease modifying treatments in multiple sclerosis. OBSERVATIONS: Although information about the mechanisms of immunity are scant, it appears that monocyte/macrophages and then CD8 T cells are important in eliminating the SARS-CoV-2 virus. This may be facilitated via anti-viral antibody responses that may prevent re-infection. However, viral escape and infection of leucocytes to promote lymphopenia, apparent CD8 T cell exhaustion coupled with a cytokine storm and vascular pathology appears to contribute to the damage in ARDS. IMPLICATIONS: In contrast to ablative haematopoietic stem cell therapy, most multiple-sclerosis-related disease modifying therapies do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19. In addition, few block the formation of immature B cells within lymphoid tissue that will provide antibody-mediated protection from (re)infection. However, adjustments to dosing schedules may help de-risk the chance of infection further and reduce the concerns of people with MS being treated during the COVID-19 pandemic.","Mult Scler Relat Disord","Baker, David","Amor, Sandra","Kang, Angray S","Schmierer, Klaus","Giovannoni, Gavin","32464584"],"abstract":["BACKGROUND: SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute respiratory distress syndrome (ARDS), which can cause significant mortality, leading to concern that immunosuppressive treatments for multiple sclerosis and other disorders have significant risks for both infection and ARDS. OBJECTIVE: To examine the biology that potentially underpins immunity to the SARS-Cov-2 virus and the immunity-induced pathology related to COVID-19 and determine how this impinges on the use of current disease modifying treatments in multiple sclerosis. OBSERVATIONS: Although information about the mechanisms of immunity are scant, it appears that monocyte/macrophages and then CD8 T cells are important in eliminating the SARS-CoV-2 virus. This may be facilitated via anti-viral antibody responses that may prevent re-infection. However, viral escape and infection of leucocytes to promote lymphopenia, apparent CD8 T cell exhaustion coupled with a cytokine storm and vascular pathology appears to contribute to the damage in ARDS. IMPLICATIONS: In contrast to ablative haematopoietic stem cell therapy, most multiple-sclerosis-related disease modifying therapies do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19. In addition, few block the formation of immature B cells within lymphoid tissue that will provide antibody-mediated protection from (re)infection. However, adjustments to dosing schedules may help de-risk the chance of infection further and reduce the concerns of people with MS being treated during the COVID-19 pandemic."],"journal":"Mult Scler Relat Disord","authors":["Baker, David","Amor, Sandra","Kang, Angray S","Schmierer, Klaus","Giovannoni, Gavin"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464584","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.msard.2020.102174","topics":["Prevention","Mechanism","Treatment"],"weight":1,"_version_":1668079521343995904,"score":218.36736},{"pmid":32469225,"title":"COVID-19 and the immune system.","text":["COVID-19 and the immune system.","A close interaction between the virus SARS-CoV-2 and the immune system of an individual results in a diverse clinical manifestation of the COVID-19 disease. While adaptive immune responses are essential for SARS-CoV-2 virus clearance, the innate immune cells, such as macrophages, may contribute, in some cases, to the disease progression. Macrophages have shown a significant production of IL-6 suggesting they may contribute to the excessive inflammation in COVID-19 disease. Macrophage Activation Syndrome may further explain the high serum levels of CRP, which are normally lacking in viral infections. In adaptive immune responses, it has been revealed that cytotoxic CD8+ T cells exhibit functional exhaustion patterns, such as the expression of NKG2A, PD-1, and TIM-3. Since SARS-CoV-2 restrains antigen presentation by downregulating MHC class I and II molecules and, therefore, inhibits the T cell-mediated immune responses, humoral immune responses also play a substantial role. Specific IgA response appears to be stronger and more persistent than IgM response. Moreover, IgM and IgG antibodies show similar dynamics in COVID-19 disease.","Physiol Res","Paces, J","Strizova, Z","Smrz, D","Cerny, J","32469225"],"abstract":["A close interaction between the virus SARS-CoV-2 and the immune system of an individual results in a diverse clinical manifestation of the COVID-19 disease. While adaptive immune responses are essential for SARS-CoV-2 virus clearance, the innate immune cells, such as macrophages, may contribute, in some cases, to the disease progression. Macrophages have shown a significant production of IL-6 suggesting they may contribute to the excessive inflammation in COVID-19 disease. Macrophage Activation Syndrome may further explain the high serum levels of CRP, which are normally lacking in viral infections. In adaptive immune responses, it has been revealed that cytotoxic CD8+ T cells exhibit functional exhaustion patterns, such as the expression of NKG2A, PD-1, and TIM-3. Since SARS-CoV-2 restrains antigen presentation by downregulating MHC class I and II molecules and, therefore, inhibits the T cell-mediated immune responses, humoral immune responses also play a substantial role. Specific IgA response appears to be stronger and more persistent than IgM response. Moreover, IgM and IgG antibodies show similar dynamics in COVID-19 disease."],"journal":"Physiol Res","authors":["Paces, J","Strizova, Z","Smrz, D","Cerny, J"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469225","source":"PubMed","week":"202022|May 25 - May 31","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887179689984,"score":217.39502},{"pmid":32345646,"title":"BTK inhibitors in cancer patients with COVID19: \"The winner will be the one who controls that chaos\" (Napoleon Bonaparte).","text":["BTK inhibitors in cancer patients with COVID19: \"The winner will be the one who controls that chaos\" (Napoleon Bonaparte).","As the SARS-CoV-2 (COVID19) pandemic spreads and the number of Bruton's tyrosine kinase inhibitor (BTKi)-treated COVID19 affected patients grows, we must consider the pros and cons of BTKi discontinuation for our patients. In favor of BTKi continuation, BTK plays an active role in macrophage polarization. By modulating key transcription factors, BTK may regulate macrophage polarization downstream of classic M1 and M2 polarizing stimuli and mitigate the hyperinflammatory state associated with COVID19. In favor of BTKi discontinuation, we note a potentially increased risk of secondary infections or impaired humoral immunity. We hypothesize that the potential benefit of blunting a hyper-inflammatory response to SARS-CoV-2 through attenuation of M1 polarization outweighs the potential risk of impaired humoral immunity, not to mention the risk of rapid progression of B-cell malignancy following BTKi interruption. Based on this, we suggest continuing BTKi in patients with COVID19.","Clin Cancer Res","Chong, Elise A","Roeker, Lindsey E","Shadman, Mazyar","Davids, Matthew S","Schuster, Stephen J","Mato, Anthony R","32345646"],"abstract":["As the SARS-CoV-2 (COVID19) pandemic spreads and the number of Bruton's tyrosine kinase inhibitor (BTKi)-treated COVID19 affected patients grows, we must consider the pros and cons of BTKi discontinuation for our patients. In favor of BTKi continuation, BTK plays an active role in macrophage polarization. By modulating key transcription factors, BTK may regulate macrophage polarization downstream of classic M1 and M2 polarizing stimuli and mitigate the hyperinflammatory state associated with COVID19. In favor of BTKi discontinuation, we note a potentially increased risk of secondary infections or impaired humoral immunity. We hypothesize that the potential benefit of blunting a hyper-inflammatory response to SARS-CoV-2 through attenuation of M1 polarization outweighs the potential risk of impaired humoral immunity, not to mention the risk of rapid progression of B-cell malignancy following BTKi interruption. Based on this, we suggest continuing BTKi in patients with COVID19."],"journal":"Clin Cancer Res","authors":["Chong, Elise A","Roeker, Lindsey E","Shadman, Mazyar","Davids, Matthew S","Schuster, Stephen J","Mato, Anthony R"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32345646","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1158/1078-0432.CCR-20-1427","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495460048896,"score":215.37793}]}